Net Cash Used in Operating Activities (Total Cash Burn) of $24.2 million USD($30.5 million CAD) for year ended December 31, 2020
NEW YORK, March 30, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, has announced its annual 2020 financial results for the year ended December 31, 2020.
2020 Financial Highlights (in USD)
- Total assets as of December 31, 2020 were $85.6 million, including $80.1 million in cash
- Net Cash Used in Operating Activities (Total Cash Burn) of $24.2 million for the year ended December 31, 2020.
- Net and comprehensive loss of $35.1 million for the year ended December 31, 2020.
Current Cash Balance
As of March 30, 2021 maintains a current cash balance of $161 million USD ($203 million CAD) to advance its portfolio and build out it’s technology division.
An earnings call will be held Thursday, April 1, 2021 at 10:00 am ET. Details are below:
Complete financial statements along with related management’s discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada at www.SEDAR.com.
MindMed is a psychedelic medicine biotech company seeking to discover, develop and deploy psychedelic inspired medicines and therapies to address addiction and mental illness. The Company is assembling a drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC.
Sign up for MORE news updates !
This article is written and published by The Cannabis Stock
Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies
The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.